The healthcare equity landscape suggests BMY stock forecast 2025 will track upward momentum if FDA clearance for its hematology assets arrives within Q2–Q3 timelines. As a result of these initiatives, Bristol-Myers Squibb Company (NYSE:BMY) is gaining favor with analysts. They believe it is well-positioned for growth as it approaches a critical period, with outcomes from 40 clinical trials on the horizon. By 2025, five new products are anticipated to contribute at least half of the company’s revenue, marking the beginning of substantial growth. A notable asset in its pipeline is Cobenfy, a schizophrenia treatment that has already outperformed other branded options in the market, showing significant commercial promise. Bristol Myers Squibb stock was up 2.98% in pre-market trading on Thursday, following a 1.88% dip yesterday. The shares have also fallen 15.82% year-to-date and 4.55% over the past 12 months. In equity research updates, BMY stock forecast 2025 reflects demand from immunology markets and strategic partnerships, a factor that may offset pricing pressures in mature therapeutics.